Published in Br J Cancer on May 04, 2001
Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med (2008) 1.28
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71
Conducting clinical research in the new NHS: the model of cancer. United Kingdom Coordinating Committee on Cancer Research. BMJ (1994) 2.70
The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population. Br J Cancer (2005) 2.66
Alternate splicing produces a novel cyclin D1 transcript. Oncogene (1995) 2.48
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer (2000) 2.30
Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer (1987) 2.18
Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.17
High-intensity focused ultrasound for the treatment of liver tumours. Ultrasonics (2004) 2.14
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer (1987) 1.97
Genetic predisposition to human lung cancer. Br J Cancer (1986) 1.94
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol (2011) 1.88
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1994) 1.79
Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology (2006) 1.77
Volunteers or victims: patients' views of randomised cancer clinical trials. Br J Cancer (1995) 1.70
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol (2003) 1.62
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol (1995) 1.61
Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma. J Clin Oncol (2000) 1.49
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer (1986) 1.45
Adjuvant interferon in the treatment of melanoma. Br J Cancer (1999) 1.39
A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer (1993) 1.38
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer (1996) 1.38
O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res (1991) 1.34
Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst (2000) 1.33
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer (2011) 1.31
Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res (1989) 1.31
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer (1998) 1.29
ACTH precursors characterize the ectopic ACTH syndrome. Clin Endocrinol (Oxf) (1994) 1.27
Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer (1992) 1.22
Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol (2011) 1.21
Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma. Br J Cancer (1977) 1.18
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol (2004) 1.17
Human lymphocyte traffic assessed by indium-111 oxine labelling: clinical observations. Clin Exp Immunol (1981) 1.16
A method for following human lymphocyte traffic using indium-111 oxine labelling. Clin Exp Immunol (1981) 1.15
In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br J Cancer (1988) 1.14
Upper abdominal lymphadenopathy as first presentation of relapse, identified by ultrasonography, in patients treated for small cell (oat cell) bronchogenic carcinoma. Br J Dis Chest (1985) 1.14
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer (2012) 1.11
Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br J Cancer (2009) 1.09
Viridans streptococcal bacteraemia in patients with haematological and solid malignancies. Eur J Cancer (1991) 1.08
Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer (1999) 1.08
Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther (2001) 1.06
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer (2006) 1.05
Melanoma: chemotherapy. Br Med Bull (1995) 1.04
G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int J Cancer (1997) 1.04
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res (2002) 1.03
O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer (2000) 1.03
Inactivation of O6-alkylguanine-DNA alkyltransferase. 1. Novel O6-(hetarylmethyl)guanines having basic rings in the side chain. J Med Chem (1998) 1.03
Three months treatment with chemotherapy and radiotherapy for small cell lung cancer. Br J Cancer (1985) 1.03
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. Br J Cancer (2008) 1.02
Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer: response and survival results. Br J Cancer (2002) 1.02
Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2. Int J Cancer (1989) 1.02
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer. Ann Oncol (1994) 1.02
The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol (2010) 1.01
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. Br J Cancer (2011) 0.99
Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene (1998) 0.99
Immunohistological examination of the inter- and intracellular distribution of O6-alkylguanine DNA-alkyltransferase in human liver and melanoma. Br J Cancer (1992) 0.98
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer (2000) 0.98
A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer (1996) 0.97
Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br J Cancer (1989) 0.97
Expression of the glial glutamate transporter EAAT2 in the human CNS: an immunohistochemical study. Brain Res Mol Brain Res (1997) 0.97
Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer (1994) 0.97
Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling. Crit Rev Oncol Hematol (2005) 0.97
Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. Br J Cancer (1993) 0.96
Radiotherapy for small-cell lung cancer-Where are we heading? Lung Cancer (2008) 0.95
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. Br J Cancer (2009) 0.95
Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study. Br J Cancer (1989) 0.95
Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol (1995) 0.94
Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol (1998) 0.94
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol (1989) 0.94
Pulmonary carcinoid tumours: a clinico-pathological study of 35 cases. Br J Cancer (1986) 0.94
The value of tumour markers in lung cancer. Br J Cancer (1988) 0.93
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer (1990) 0.93
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int J Cancer (2000) 0.93
Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol (1995) 0.93
Phase I clinical trial of methylene dimethane sulfonate. Cancer Treat Rep (1987) 0.93
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol (2007) 0.93
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. Ann Oncol (2014) 0.92
Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology (2006) 0.92
Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer (1993) 0.92
Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer. Eur Radiol (2010) 0.92
The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol (1989) 0.92
The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmacol (1990) 0.92
Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer (2008) 0.91
A simple quantitative HPLC assay for ifosfamide in biological fluids. Biomed Chromatogr (1986) 0.91
Recombinant human interleukin-4 (rhu IL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer--a phase I toxicity study and pharmacokinetic analysis. Eur J Cancer (1993) 0.91
Immunoscintigraphy with 99mTc labelled F(ab')2 fragments of an anti melanoma monoclonal antibody (225.28S) in patients with metastatic malignant melanoma. Eur J Nucl Med (1987) 0.91
Changes in cellular immunity following nephrectomy for localized and metastatic hypernephroma. Eur J Cancer (1977) 0.91
Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma. Br J Surg (2012) 0.91
Treatment of malignant pleural effusions with intrapleural Corynebacterium parvum or tetracycline. Eur J Respir Dis (1985) 0.91
Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. Drugs (2015) 0.90
Bioavailability of ifosfamide in patients with bronchial carcinoma. Cancer Chemother Pharmacol (1986) 0.90
Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations. Clin Exp Immunol (1979) 0.90
Activity of JM9 in advanced ovarian cancer: a phase I-II trial. Cancer Treat Rep (1985) 0.90